Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to exp...
Q1 2026
May 29, 2026
FY 2025
Mar 25, 2026
Q4 2025
Q3 2025
Nov 7, 2025
Q2 2025
Aug 8, 2025